0.799

1.31% -0.0029

Rani Therapeutics Holdings Inc (RANI)

Overview News Price History Option Chain Financials Discussions Forecast

Rani Therapeutics Holdings Inc stock is traded at $0.799, with a volume of 277.66K. It is down -1.31% in the last 24 hours and up +12.68% over the past month. Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Previous Close:

$0.7961

Open:

$0.81

24h Volume:

277.66K

Relative Volume:

0.31

Market Cap:

$89.84M

Revenue:

$3.17M

Net Income/Loss:

$-36.23M

P/E Ratio:

-1.9545

EPS:

-0.4088

Net Cash Flow:

$-17.11M

1W Performance:

+1.13%

1M Performance:

+12.68%

6M Performance:

-38.62%

1Y Performance:

+42.85%

1-Day Range:

$0.7751

$0.816

1-Week Range:

$0.7701

$0.8238

52-Week Range:

$0.4404

$3.87

Rani Therapeutics Holdings Inc Stock (RANI) Company Profile

Name

Rani Therapeutics Holdings Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

(408) 457-3700

Address

2051 RINGWOOD AVENUE, SAN JOSE

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

RANI's Discussions on Twitter

Compare RANI vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RANI Rani Therapeutics Holdings Inc	0.7994	89.47M	3.17M	-36.23M	-17.11M	-0.4088
VRTX Vertex Pharmaceuticals Inc	515.31	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.34	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.59	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.54	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.30	39.31B	5.76B	514.49M	1.10B	4.4813

Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-14-26	Initiated	Lake Street	Buy
Aug-02-24	Initiated	Oppenheimer	Outperform
Jun-14-24	Initiated	Maxim Group	Buy
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Apr-17-23	Resumed	BTIG Research	Buy
Oct-11-22	Initiated	UBS	Buy
Jul-27-22	Initiated	H.C. Wainwright	Buy
Jun-13-22	Initiated	Wedbush	Outperform

View All

Rani Therapeutics Holdings Inc Stock (RANI) Latest News

Aug 16, 2026

Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline - MarketBeat

Aug 16, 2026

Aug 14, 2026

Rani Therapeutics | SCHEDULE 13G/A: Others - Moomoo

Aug 14, 2026

RA Capital details 11,530,414 Rani Therapeutics (RANI) shares under 9.99% cap - Stock Titan

Aug 14, 2026

Rani Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo

Aug 14, 2026

Rani Therapeutics Holdings earnings beat by $0.01, revenue topped estimates - Investing.com Canada

Aug 14, 2026

Aug 13, 2026

8-K: Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Updatemoomoo - Moomoo

Aug 13, 2026

Rani Therapeutics (NASDAQ:RANI) Announces Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat

Aug 13, 2026

Rani Therapeutics Q2 Results: EPS beats estimate, sales up 85% - scanx.trade

Aug 13, 2026

Rani Therapeutics (RANI) boosts liquidity with $20M raise and Chugai revenue - Stock Titan

Aug 13, 2026

Rani Therapeutics reports Q2 2026: $1.7M contract revenue, $8.4M quarterly net loss, $53.4M cash - TradingView

Aug 13, 2026

Rani Therapeutics' Oral RT-114 Tops 150% Bioavailability - Stock Titan

Aug 13, 2026

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update - GlobeNewswire

Aug 13, 2026

Aug 12, 2026

Rani Therapeutics at Canaccord Genuity conference: oral biologics push By Investing.com - Investing.com Canada

Aug 12, 2026

RANI: Oral biologics platform shows strong clinical and business momentum, with funding secured into 2027 - TradingView

Aug 12, 2026

Aug 10, 2026

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference - The Manila Times

Aug 10, 2026

Rani Therapeutics CEO, CFO to Present, Hold 1x1 Meetings Aug. 12 - Stock Titan

Aug 10, 2026

IMDX Stock Price and Chart — NASDAQ:IMDX - TradingView

Aug 10, 2026

Aug 06, 2026